Farmas USA

Si no nos rebotan hoy bien y sobre todo con volumen se nos van al carajo,,,,puse ayer orden de compra a 24 por si sonaba la flauta pero no entraron ni de cerca,,,,,saludos Shirfos.

NETE.

Nuevo maximo premarket: 12,70$

De momento el volumen es ridiculo, 3k cromos ... es pronto, los usanos aun andan con legañas.

NVAX

NVAX,,por arriba no tiene nada ,,solo el cielo.Y viendo como estan las farmas ultimamente........

Amarin Promotes Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives

BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/11/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the promotion of Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives.

With more than 20 years of industry experience, Mr. Kennedy has contributed significantly to progress at Amarin since joining the company in December 2011 as Senior Vice President, General Counsel. Kennedy's recent accomplishments include his role in leading Amarin to two significant federal court rulings: The First Amendment-based federal court declaration allowing Amarin's promotion of truthful and non-misleading off-label information about Vascepa^® (icosapent ethyl) capsules and the first successful judicial challenge to a denial of five-year, NCE exclusivity since the Hatch-Waxman Act was passed in 1984. Kennedy is also credited with leading Amarin's strategy in the successful prosecution of over 40 patents designed to protect the Vascepa franchise into 2030 and in the recent dismissal of a securities class action suit against Amarin. He also played an important role supporting Amarin business development in the establishment of Amarin's U.S. Vascepa co-promotion agreement with Kowa Pharmaceutical America, Inc. and collaboration agreement with Eddingpharm in greater China.

"On behalf of Amarin and its Board of Directors, it is with great pleasure that I announce Joe's promotion and recognize his important contributions to the strength and development of Amarin," stated John F. Thero, President and Chief Executive Officer of Amarin. "Joe's skillful dedication and leadership have contributed meaningfully to our success and his efforts have made Amarin a leader on issues important to the life science industry and in support of our mission to improve the lives of patients."

Mr. Kennedy joined Amarin with an impressive record of achievement in the life science industry. In 2010, he was recognized by the President of Ireland as one of the inaugural, "Irish Life Science 50," which honored Irish-Americans for outstanding contributions to the industry. He served as Vice President, General Counsel at Transcept Pharmaceuticals, Inc., where he played a lead role negotiating the company's strategic collaboration with Purdue Pharma, secured key patents, and helped design the strategy to obtain FDA approval for the company's lead product following two Complete Response Letters from FDA. Mr. Kennedy also served as the chief legal officer of Eyetech Pharmaceuticals, Inc. through sale of the company to OSI Pharmaceuticals Inc. Previously, Mr. Kennedy served as Vice President and U.S. Counsel, Corporate Business Development, with Élan Corporation, plc where he helped acquire technologies, manage multiple collaborations and participated in the company's sale of $2.0 billion in assets. Mr. Kennedy previously practiced law with Orrick, Herrington & Sutcliffe LLP where he represented investment banks and developing companies in initial public offerings and mergers and acquisitions.

AMRN

Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC)

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/11/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the company, in collaboration with the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), has initiated the first Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" (TH-4000), for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR tyrosine kinase inhibitor and are progressing on treatment, but have not acquired the T790M resistance mutation. Tarloxotinib is Threshold's proprietary, hypoxia-activated, irreversible EGFR tyrosine kinase inhibitor licensed from the University of Auckland, New Zealand.

"While there has been recent progress in treating EGFR-mutant patients with acquired resistance to first-generation drugs driven through T790M mutations, an urgent need exists to develop treatments for patients whose disease has progressed due to other mechanisms of resistance," said D. Ross Camidge, M.D., Ph.D., Professor of Medicine/Oncology at the University of Colorado School of Medicine and Director of ATOMIC. "ATOMIC is committed to advancing the next generation of therapies for lung cancer, quickly, scientifically and efficiently. We are excited to collaborate with Threshold and begin this Phase 2 clinical trial of tarloxotinib, which has demonstrated, in preclinical studies, an ability to overcome resistance to conventional EGFR tyrosine kinase inhibitors at clinically relevant dose levels."

Aberrant EGFR signaling is implicated in the growth and spread of certain tumor types including NSCLC. The majority of patients with EGFR-mutant NSCLC who are treated with a currently available EGFR tyrosine kinase inhibitor, such as Tarceva® (erlotinib), Gilotrif® (afatinib) and Iressa® (gefitinib), will develop resistance, due to a variety of mechanisms, to these targeted therapies in about a year.

"One largely unexplored mechanism of acquired resistance is through expression of not only mutant EGFR but also the normal 'wild-type' form of the receptor and its subsequent stimulation by growth factors produced in the tumor microenvironment," said Stephen V. Liu, M.D., Assistant Professor at Georgetown University and Principal Investigator of the Phase 2 clinical trial. "Unfortunately, the side effects of current EGFR tyrosine kinase inhibitors, including rash and diarrhea, prevent maximally efficacious inhibition of 'wild-type' EGFR in the tumor from being achieved. These side effects are mediated by non-targeted, systemic inhibition of 'wild-type' EGFR. In contrast, tarloxotinib is a prodrug designed to be preferentially activated in hypoxic, or low-oxygen, conditions commonly found in solid tumors including EGFR-mutant NSCLC, which may allow greater inhibition of EGFR signaling within the tumor while limiting the systemic side effects."

The Phase 2 clinical trial is a single-arm, open label study that will enroll up to 37 patients with Stage IV NSCLC who have a sensitizing EGFR mutation and who have progressed on EGFR tyrosine kinase inhibitor therapy (with no intervening therapy), and who subsequently test negative for the T790M mutation on post-progression biopsy. Eligible patients will receive tarloxotinib (150 mg/m2 by intravenous infusion) on Days 1, 8, 15 and 22 of a 28-day cycle. RECIST response rate is the primary endpoint. Secondary endpoints include duration of response, progression-free survival, overall survival, safety, tolerability and pharmacokinetics. In addition to other target-specific biomarkers, hypoxia status will be measured at baseline using Threshold's proprietary PET imaging agent [18F]-HX4. The study will be open at 12 sites in the U.S. and Australia.

"The initiation of this Phase 2 clinical trial marks a significant milestone for the development of tarloxotinib," said Tillman Pearce, M.D., Chief Medical Officer of Threshold. "Threshold now has the two most advanced hypoxia-activated prodrugs in clinical development, including evofosfamide, which is under investigation in two fully-enrolled, pivotal Phase 3 clinical trials. We are excited to collaborate with ATOMIC on evaluating tarloxotinib as a hypoxia-activated, molecularly-targeted prodrug in a selected population of patients with EGFR-mutant NSCLC. We plan to initiate a second Phase 2 trial of tarloxotinib in patients with advanced head and neck cancer this year."

Framus, sigue en pie la idea de soltar tus 3/4 de cromos a 15?? Lo digo porque igual hoy es el día, jeje. Es pregunta retórica, no hace falta que respondas si no quieres, jeje.
NVAX

Digo a partir de ahora. Ayer estaba muy cabreado y claro que la lié. El timming fue malo, así no puedo hacer las cosas en un futuro, pero al menos tampoco veo precios horribles ni empresas que no quisiera tener en cartera .